Natsumi T. Hamahata
Natsumi T. Hamahata has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ali Al‐Khafaji
Department of Critical Care Medicine Center for Critical Care Nephrology University of Pittsburgh Pittsburgh Pennsylvania USA
1 shared publicationAnkit Sakhuja
Department of Medicine and Institute for Critical Care Medicine Icahn School of Medicine, Mount Sinai New York New York USA
1 shared publicationDavid J. Kaczorowski
Department of Cardiothoracic Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
1 shared publication- Ernest G. Chan
Department of Cardiothoracic Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
1 shared publication Hernando Gómez
Department of Critical Care Medicine Center for Critical Care Nephrology University of Pittsburgh Pittsburgh Pennsylvania USA
1 shared publication- Ivan Eb Saraiva
Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
1 shared publication
Latest Publications
- 5 December 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (10) , e279-e286
Prognosis of Immunocompromised Patients With Respiratory Failure Managed With Venovenous Extracorporeal Membrane Oxygenation
Despite the increasing number of critically ill immunocompromised patients in intensive care unit, the outcome of different types of immunocompromised patients with respiratory failure managed with venovenous extracorporeal membrane oxygenation (VV ECMO) remains unclear. What is the overall mortality of immunocompromised patients with respiratory failure managed on VV ECMO compared to immunocompetent patients? Are there differences between different types of immunocompromised states? This is a systematic review and meta-analysis using MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for studies of any design that reported outcomes of immunocompromised adult patients managed on VV ECMO for respiratory failure. A total of 13 studies were included. The pooled mortality among immunocompromised patients undergoing VV ECMO was 63% (95% confidence interval [CI]: 49–76%, I 2 : 94.23%), which was significantly higher than immunocompetent patients (odds ratio [OR]: 2.57, 95% CI: 1.22–5.41, p = 0.03, I 2 : 48.18%). Among immunocompromised subgroups, only patients with hematologic malignancy exhibited significantly higher mortality (OR: 5.78, 95% CI: 1.07–31.29, p = 0.05, I 2 : 0.00%). Immunocompromised patients with acute respiratory failure treated with VV ECMO were associated with higher mortality compared to immunocompetent patients. Mortality varied by underlying cause of immunosuppression, emphasizing the need for careful, individualized patient selection.
- 5 December 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (10) , e279-e286
Prognosis of Immunocompromised Patients With Respiratory Failure Managed With Venovenous Extracorporeal Membrane Oxygenation
Despite the increasing number of critically ill immunocompromised patients in intensive care unit, the outcome of different types of immunocompromised patients with respiratory failure managed with venovenous extracorporeal membrane oxygenation (VV ECMO) remains unclear. What is the overall mortality of immunocompromised patients with respiratory failure managed on VV ECMO compared to immunocompetent patients? Are there differences between different types of immunocompromised states? This is a systematic review and meta-analysis using MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for studies of any design that reported outcomes of immunocompromised adult patients managed on VV ECMO for respiratory failure. A total of 13 studies were included. The pooled mortality among immunocompromised patients undergoing VV ECMO was 63% (95% confidence interval [CI]: 49–76%, I 2 : 94.23%), which was significantly higher than immunocompetent patients (odds ratio [OR]: 2.57, 95% CI: 1.22–5.41, p = 0.03, I 2 : 48.18%). Among immunocompromised subgroups, only patients with hematologic malignancy exhibited significantly higher mortality (OR: 5.78, 95% CI: 1.07–31.29, p = 0.05, I 2 : 0.00%). Immunocompromised patients with acute respiratory failure treated with VV ECMO were associated with higher mortality compared to immunocompetent patients. Mortality varied by underlying cause of immunosuppression, emphasizing the need for careful, individualized patient selection.
- 27 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15444
Risk Factors and Outcomes Associated With the Development of Persistent Acute Kidney Injury in Non‐Renal Solid Organ Transplant Recipients: Systematic Review and Meta‐Analysis
Persistent acute kidney injury (pAKI), compared with acute kidney injury (AKI) that resolves in 2. We identified 25 studies including 6330 patients. AKI (8%–71.6%) and pAKI (2.7%–55.1%) varied widely. Definitions of pAKI included 48–72 h (six studies), 7 days (three studies), 14 days (four studies), or more (12 studies). Risk factors included age, body mass index (BMI), diabetes, preoperative chronic kidney disease (CKD), intraoperative vasopressor use, and intraoperative circulatory support. pAKI was associated with new onset of CKD (odds ratio [OR] 1.41–11.2), graft dysfunction (OR 1.81–8.51), and long‐term mortality (OR 3.01–13.96), although significant heterogeneity limited certainty of CKD and graft dysfunction outcome analyses. pAKI is common and is associated with worse mortality among liver and lung transplant recipients. Standardization of the nomenclature of AKI will be important in future studies (PROSPERO CRD42022371952).
- 27 August 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15444
Risk Factors and Outcomes Associated With the Development of Persistent Acute Kidney Injury in Non‐Renal Solid Organ Transplant Recipients: Systematic Review and Meta‐Analysis
Persistent acute kidney injury (pAKI), compared with acute kidney injury (AKI) that resolves in 2. We identified 25 studies including 6330 patients. AKI (8%–71.6%) and pAKI (2.7%–55.1%) varied widely. Definitions of pAKI included 48–72 h (six studies), 7 days (three studies), 14 days (four studies), or more (12 studies). Risk factors included age, body mass index (BMI), diabetes, preoperative chronic kidney disease (CKD), intraoperative vasopressor use, and intraoperative circulatory support. pAKI was associated with new onset of CKD (odds ratio [OR] 1.41–11.2), graft dysfunction (OR 1.81–8.51), and long‐term mortality (OR 3.01–13.96), although significant heterogeneity limited certainty of CKD and graft dysfunction outcome analyses. pAKI is common and is associated with worse mortality among liver and lung transplant recipients. Standardization of the nomenclature of AKI will be important in future studies (PROSPERO CRD42022371952).